Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

← Back to the feed

Dascoli Pharma AG

History from 2 Nov 2022

UID
CHE-172.957.423
Legal form
AG
Canton
ZH
Founded
2 Nov 2022
Amount raised
not in the SHAB
Lead investor
not in the SHAB
Nominal capital · CHFCHF 115k
29k57k86k115k10 Sep 2026 · CHF 115k
  • shares

Record

  1. Company formed

    Founded 2 Nov 2022

    SHAB HR01-1005597774 ↗
  2. Capital increase

    Likely financing

    Paid in cash and by other means

    Nominal capital
    100’000 → 114’740.30
    Shares
    1’000’000 → 1’147’403
    New shares, % of post-step shares
    12.8% (147’403 new)

    Aktienkapital neu: CHF 114'740.30 [bisher: CHF 100'000.00]. Liberierung Aktienkapital neu: CHF 114'740.30 [bisher: CHF 100'000.00]. Aktien neu: 1'147'403 Namenaktien zu CHF 0.10 [bisher: 1'000'000 Namenaktien zu CHF 0.10].

    From the SHAB entry · German original, person names removed · not an official copy · full entry ↗
    • The increase is an odd amount in small-nominal shares, as priced rounds usually are.+1.0
    • The company was founded less than six years before this capital increase.+0.5
    • The company's purpose describes technology or life-sciences development.+0.5

    Classifier score 0.60 · likely-financing threshold 0.60 · not a calibrated probability

    SHAB HR02-1006752752 ↗

Published by 13 Sep 2026

Latest available record · 8 Oct 2026